Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

31.08.22	Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older (Businesswire)
26.08.22	Pfizer, BioNTech Complete Submission To EMA For Omicron BA.4/BA.5 Adapted Bivalent Vaccine (RTTNews)
26.08.22	Moderna Sues Pfizer, BioNTech For Patent Infringement (RTTNews)
25.08.22	Pfizer Announces Positive Data From Late-stage Study Of RSV Vaccine Candidate (RTTNews)
25.08.22	Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate (Businesswire)
24.08.22	Pfizer's Hospira Recalls Propofol Injectable Emulsion (RTTNews)
23.08.22	Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age (Businesswire)
22.08.22	Pfizer Submits Application To FDA For Emergency Nod Of Omicron BA.4/BA.5 Bivalent COVID-19 Vaccine (RTTNews)
22.08.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine (Businesswire)
19.08.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
12.08.22	Pfizer: Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine Posts Positive Results In Infants (RTTNews)
12.08.22	Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants (Businesswire)
09.08.22	Pfizer, Valneva Initiate Phase 3 Study Of Lyme Disease Vaccine Candidate VLA15 (RTTNews)
08.08.22	Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 (Businesswire)
08.08.22	Pfizer To Buy Global Blood Therapeutics In $5.4 Bln All-cash Deal (RTTNews)
08.08.22	BioNTech Q2 Results Down, Backs FY22 Vaccine Revenue View; Stock Down (RTTNews)
08.08.22	Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology (Businesswire)
28.07.22	Pfizer Q2 Results Climb, Beat Estimates; Lifts Low-end Of FY22 Adj. EPS View (RTTNews)
28.07.22	Pfizer Inc. Q2 Profit Increases, beats estimates (RTTNews)
28.07.22	PFIZER REPORTS SECOND-QUARTER 2022 RESULTS (Businesswire)
27.07.22	Pfizer, BioNTech Advance COVID-19 Vaccine Strategy With Next-Gen Vaccine Candidate Study (RTTNews)
27.07.22	General statement of acquisition of beneficial ownership (RSS)
09.07.22	Pfizer Submits Variation To EMA For COVID-19 Vaccination Of Children 6 Months To Less Than 5 Yrs (RTTNews)
09.07.22	FDA Approves Pfizer's COVID-19 Vaccine For Adolescents (RTTNews)
07.07.22	FDA Says Pharmacists Can Prescribe Pfizer COVID-19 Pill Paxlovid (RTTNews)
30.06.22	Pfizer Submits NDA For PAXLOVID To FDA To Treat Severe Illness From COVID-19 (RTTNews)
30.06.22	Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ (Businesswire)
30.06.22	Pfizer Signs $3.2 Bln COVID Vaccine Deal With US Government (RTTNews)
30.06.22	Pfizer And BioNTech Reach New Agreement With U.S. To Provide Addl Doses Of COVID-19 Vaccine (RTTNews)
29.06.22	Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine (Businesswire)
29.06.22	FDA Experts Recommend Updated Booster Shots To Fight Contagious Omicron Variant In Fall (RTTNews)
29.06.22	Statement of acquisition of beneficial ownership by individuals (RSS)
28.06.22	Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus (Businesswire)
28.06.22	Statement of acquisition of beneficial ownership by individuals (RSS)
25.06.22	Pfizer, BioNTech Report Positive Data From Omicron-adapted COVID-19 Vaccine Candidate Trial (RTTNews)
25.06.22	Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron (Businesswire)
24.06.22	Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts (Businesswire)
24.06.22	Basilea' Partner Pfizer Gets Approval In China For Addl Formulation Of Antifungal Cresemba In China (RTTNews)
23.06.22	Pfizer Declares Third-Quarter 2022 Dividend (Businesswire)
20.06.22	Pfizer To Invest $95 Mln In Valneva; Updates Deal Terms For Lyme Disease Vaccine Candidate VLA15 (RTTNews)
20.06.22	Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 (Businesswire)
17.06.22	FDA Authorizes Pfizer COVID-19 Vaccine For Children Between 6 Months - 4 Yrs (RTTNews)
17.06.22	Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age (Businesswire)
16.06.22	FDA Advisers Recommend Pfizer, Moderna COVID-19 Vaccines For Kids As Young As 6 Months (RTTNews)
15.06.22	Pfizer Halts Enrollment For Covid-19 Drug Paxlovid In Standard-risk Groups (RTTNews)
15.06.22	FDA Advisers Recommend Moderna Covid-19 Vaccine For Ages 6 To 17 (RTTNews)
14.06.22	Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA (Businesswire)
13.06.22	Pfizer COVID Vaccine Safe And Effective For Kids Under 5: FDA Staff (RTTNews)
09.06.22	Pfizer Completes Acquisition of ReViral (Businesswire)
09.06.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester

22.11.24

Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone

22.11.24

Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün